Morgan Stanley analyst Mark Purcell raised the firm’s price target on AstraZeneca to 12,900 GBp from 12,700 GBp and keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca call volume above normal and directionally bullish
- Microsoft upgraded, Nike downgraded: Wall Street’s top analyst calls
- AstraZeneca upgraded to Buy from Hold at Jefferies
- AstraZeneca says Dato-DXd showed significant improvement for primary endpoint
- AstraZeneca says Dato-DXd improved PFS in breast cancer trial